Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol

References

• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• MiravitllesMSorianoJBGarcia-RioFPrevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activitiesThorax2009641086386819553233
   PubMed Web of Science ®Google Scholar
• Lopez-CamposJLTanWSorianoJBGlobal burden of COPDRespirology2016211142326494423
   PubMed Web of Science ®Google Scholar
• SanduzziABalboPCandoliPCOPD: adherence to therapyMultidiscip Respir Med2014916025485108
   PubMedGoogle Scholar
• ChrystynHSmallMMilliganGHigginsVGilEGEstruchJImpact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPDRespir Med2014108235836524209768
   PubMed Web of Science ®Google Scholar
• FromerLGoodwinEWalshJCustomizing inhaled therapy to meet the needs of COPD patientsPostgrad Med20101222839320203459
   PubMed Web of Science ®Google Scholar
• BuelsKSFryerADMuscarinic receptor antagonists: effects on pulmonary functionHandb Exp Pharmacol2012208317341
   Google Scholar
• CorsicoAFulgoniPBeccariaMEffects of exercise and beta 2-agonists on lung function in chronic obstructive pulmonary diseaseJ Appl Physiol (1985)20029362053205812391117
   PubMed Web of Science ®Google Scholar
• BarnesPJInhaled corticosteroidsPharmaceuticals (Basel)20103351454027713266
   PubMedGoogle Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• CurrieGPLipworthBJPharmacological management-inhaled treatmentBMJ200633275551439144116777889
   PubMed Web of Science ®Google Scholar
• BarnesPJInhaled corticosteroids in COPD: a controversyRespiration2010802899520501985
   PubMed Web of Science ®Google Scholar
• HarriesTHSeedPTJonesSSchofieldPWhitePChronic obstructive pulmonary disease hospital admissions and drugs-unexpected positive associations: a retrospective general practice cohort studyNPJ Prim Care Respir Med2014241400624842126
   PubMed Web of Science ®Google Scholar
• LeeSDXieCMYunusFEfficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East AsiaRespirology201621111912726394882
   PubMed Web of Science ®Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax200863759259818245142
   PubMed Web of Science ®Google Scholar
• JungKSParkHYParkSYKorea Chronic Obstructive Pulmonary Disease study groupComparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled studyRespir Med2012106338238921975275
   PubMed Web of Science ®Google Scholar
• LiuYShiHSunXBenefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysisEur J Intern Med201425549149524816076
   PubMed Web of Science ®Google Scholar
• MalerbaMNardinMSantiniGMoresNRadaeliAMontuschiPSingle-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospectsTher Adv Respir Dis201812175346661876077929537340
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• ManoharanAShortPMAndersonWJLipworthBJImpact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort studyLung2014192564965224952426
   PubMed Web of Science ®Google Scholar
• KraemerMEllisABaldwinMJansenJPCapkun-NiggliGCopeSPRS5 dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD. A network meta-analysis of FEV1Value Health2012157A560
   Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWISDOM InvestigatorsWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• Di MarcoFSantusPTerraneoSCharacteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian studyNPJ Prim Care Respir Med20172715128883469
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD010115
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD002991
   PubMed Web of Science ®Google Scholar
• ChoKHKimYSLintonJANamCMChoiYParkECEffects of inhaled corticosteroids/long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: a nationwide cohort study 2002–2013Respir Med2017130758429206637
   PubMed Web of Science ®Google Scholar
• BabuKSMorjariaJBUmeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapyTher Adv Chronic Dis201784–5819128491268
   PubMed Web of Science ®Google Scholar
• MalerbaMMorjariaJBRadaeliADifferential pharmacology and clinical utility of emerging combination treatments in the management of COPD-role of umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2014968769525061288
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
   PubMed Web of Science ®Google Scholar
• ZhengJZhongNNewlandsAChurchAGohAHEfficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyInt J Chron Obstruct Pulmon Dis2015101753176726366068
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiAMateraMGNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterolDrug Des Devel Ther2013712011208
   PubMed Web of Science ®Google Scholar
• KerwinEMKalbergCJGalkinDVUmeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week studyInt J Chron Obstruct Pulmon Dis20171274575528280319
   PubMed Web of Science ®Google Scholar
• SilerTMDonaldACO’DellDChurchAFahyWAA randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mug on health-related quality of life in patients with COPDInt J Chron Obstruct Pulmon Dis20161197197927274218
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studiesRespir Med201510991155116326117292
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• BremnerPRBirkRBrealeyNIsmailaASZhuCQLipsonDASingle-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority studyRespir Res20181911929370819
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNIMPACT InvestigatorsOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaireAm Rev Respir Dis19921456132113271595997
   PubMed Web of Science ®Google Scholar
• KatsuraHYamadaKKidaKUsefulness of a linear analog scale questionnaire to measure health-related quality of life in elderly patients with chronic obstructive pulmonary diseaseJ Am Geriatr Soc20035181131113512890078
   PubMed Web of Science ®Google Scholar
• BarrJTSchumacherGEFreemanSLeMoineMBakstAWJonesPWAmerican translation, modification, and validation of the St. George’s respiratory questionnaireClin Ther20002291121114511048909
   PubMed Web of Science ®Google Scholar
• GuptaNPintoLMMoroganABourbeauJThe COPD assessment test: a systematic reviewEur Respir J201444487388424993906
   PubMed Web of Science ®Google Scholar
• TabbererMLomasDABirkROnce-daily triple therapy in patients with COPD: patient-reported symptoms and quality of lifeAdv Ther2018351567129313286
   PubMed Web of Science ®Google Scholar
• IsmailaASBirkRShahDOnce-daily triple therapy in patients with advanced COPD: healthcare resource utilization data and associated costs from the FULFIL trialAdv Ther20173492163217228875459
   PubMed Web of Science ®Google Scholar
• AlbertsonTEHarperRMurinSSandrockCPatient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterolPatient Prefer Adherence2015923524225673975
   PubMed Web of Science ®Google Scholar
• LibbyAMFishDNHosokawaPWPatient-level medication regimen complexity across populations with chronic diseaseClin Ther2013354385e1398.e123541707
   PubMed Web of Science ®Google Scholar
• Carr-LopezSMShekALastimosaJMedication adherence behaviors of medicare beneficiariesPatient Prefer Adherence201481277128425258521
   PubMed Web of Science ®Google Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesAm J Manag Care2009156e22e3319514806
   PubMed Web of Science ®Google Scholar
• ColemanCILimoneBSobierajDMDosing frequency and medication adherence in chronic diseaseJ Manag Care Pharm201218752753922971206
   PubMed Web of Science ®Google Scholar
• ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011105343544120880687
   PubMed Web of Science ®Google Scholar
• YuAPGuerinAde LeonDPClinical and economic outcomes of multiple versus single long-acting inhalers in COPDRespir Med2011105121861187121807487
   PubMed Web of Science ®Google Scholar
• LavoriniFInhaled drug delivery in the hands of the patientJ Aerosol Med Pulm Drug Deliv201427641441825238005
   PubMed Web of Science ®Google Scholar
• MelaniASInhalatory therapy training: a priority challenge for the physicianActa Biomed200778323324518330086
   PubMedGoogle Scholar
• DarbaJRamirezGSicrasAFrancoliPTorvinenSSanchez-de la RosaRThe importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patientsInt J Chron Obstruct Pulmon Dis2015102335234526604733
   PubMed Web of Science ®Google Scholar
• RamadanWHSarkisATPatterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: an observational comparative studyChron Respir Dis201714330932028774201
   PubMed Web of Science ®Google Scholar
• AroraPKumarLVohraVEvaluating the technique of using inhalation device in COPD and bronchial asthma patientsRespir Med2014108799299824873874
   PubMed Web of Science ®Google Scholar
• JonesTLNevilleDMChauhanAJThe Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptabilityTher Deliv20189316917629424288
   PubMed Web of Science ®Google Scholar
• GrantACWalkerRHamiltonMGarrillKThe ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregiversJ Aerosol Med Pulm Drug Deliv201528647448526372466
   PubMed Web of Science ®Google Scholar
• SvedsaterHDalePGarrillKWalkerRWoepseMWQualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123
   PubMed Web of Science ®Google Scholar
• van der PalenJThomasMChrystynHA randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devicesNPJ Prim Care Respir Med2016261607927883002
   PubMed Web of Science ®Google Scholar
• Yun KirbySZhuCQKerwinEMStanfordRHGeorgesGA preference study of two placebo dry powder inhalers in adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPICOPD201613216717526516724
   PubMedGoogle Scholar
• CollisonKAPatelPPreeceAFStanfordRHSharmaRKFeldmanGA randomized clinical trial comparing the ELLIPTA and HandiHaler dry powder inhalers in patients with COPD: inhaler-specific attributes and overall patient preferenceCOPD2018151465029227727
   PubMedGoogle Scholar
• KomaseYAsakoAKobayashiASharmaREase-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or olderInt J Chron Obstruct Pulmon Dis201491365137525525354
   PubMed Web of Science ®Google Scholar
• BremnerPRBirkRBrealeyNIsmailaASZhuCQLipsonDASingle-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority studyRespir Res20181911929370819
   PubMed Web of Science ®Google Scholar
• BrealeyNGuptaARenauxJMehtaRAllenAHendersonAPharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteersInt J Clin Pharmacol Ther201553975376426227101
   PubMed Web of Science ®Google Scholar